Equity · Healthcare
AUTL
NASDAQAutolus Therapeutics (AUTL)
The line runs 2.34 USD on 24 August through 0.9037 USD on 20 November, on a scale from 0.5 to 2.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 240.7M USD
- Revenue, year to Dec 2025
- 75.4M USD
- EPS, diluted, year to Dec 2025
- −1.08 USD
- 52-week range
- 0.9037 USD – 2.54 USD
- Avg volume
- 196.6K
as of Nov 20, 2026
Have Autolus Therapeutics (AUTL) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Autolus Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Sep 2026, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 2 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Sep 2026 | Piccina CintiaU.S. CCO & Country Gen Manager | Sell | 6,713 | 16K USD |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Sep 2026 | Piccina CintiaU.S. CCO & Country Gen Manager | Option exercise | 20,000 | 47K USD |
Which funds hold Autolus Therapeutics (AUTL)?
5 of the 45 institutional funds we track reported a Autolus Therapeutics position for the quarter ended 30 Sep 2026 — a combined 12.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Added | 2,492,900 | 4.8M USD | +25.6% |
| Millennium Management | Added | 2,164,182 | 4.2M USD | +76.7% |
| Citadel Advisors | Added | 1,630,469 | 3.2M USD | +134.3% |
| Point72 Asset Management | Added | 134,420 | 261K USD | +88.7% |
| Two Sigma Investments | New position | 106,889 | 207K USD | |
| Balyasny Asset Management | Exited | |||
| Marshall Wace | Exited |
What has been filed or recorded for Autolus Therapeutics (AUTL)?
The filings we hold for Autolus Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 19 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,210 shares | 4K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.21 USD | |
| 30 Sep 2026 | Financials | Total assets | 523.1M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 27.4M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.15 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.27 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.08 USD | |
| 31 Dec 2025 | Financials | Revenue | 75.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −287.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.08 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.30 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.18 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.26 USD | Revenue $9M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.86 USD | Revenue $10M |
What do people ask about Autolus Therapeutics (AUTL)?
What did Autolus Therapeutics shares close at?0.9037
Autolus Therapeutics closed at 0.9037 USD on 20 Nov 2026, down 7.36% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Autolus Therapeutics’ market cap?240.7M
Autolus Therapeutics is worth 240.7M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Autolus Therapeutics’ revenue?75.4M
Autolus Therapeutics reported revenue of 75.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Autolus Therapeutics insiders bought or sold shares recently?1 sale
In the 90 days to 22 Nov 2026, Autolus Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Sep 2026, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Autolus Therapeutics?5 of 45
5 of the 45 funds we track reported a Autolus Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Millennium Management and Citadel Advisors. See Funds
When did Autolus Therapeutics last report earnings?−0.21
Autolus Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.21 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words